uniQure NV QURE
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
uniQure Announces Third Quarter 2026 Financial Results and Provides Company Update
uniQure Announces FDA Acceptance and Priority Review of the Biologics License Application for ifezuntirgene inilparvovec for the Treatment of Huntington’s Disease
uniQure to Announce Third Quarter 2026 Financial Results
UNIQURE N.V. QURE INVESTORS: Contact Kirby McInerney LLP About the Firm’s Securities Investigation Following 37.3% Share Drop
uniQure Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into uniQure (QURE)
QURE Investors Have Opportunity to Join uniQure N.V. Fraud Investigation with SBS Law
uniQure Announces Additional Data from Ongoing Phase I/II Studies of ifezuntirgene inilparvovec (AMT-130) in Huntington’s Disease Showing Continued Slowing of Disease Progression
uniQure Announces Submission of Biologics License Application for Ifezuntirgene Inilparvovec (AMT-130) in Huntington’s Disease
Trading Information
- Previous Close Price
- $24.63
- Day Range
- $23.34–24.50
- 52-Week Range
- $8.73–51.72
- Bid/Ask
- $23.66 / $24.44
- Shares Outstanding
- 70.14M
- Market Cap
- $1.67B
- Volume/Avg
- 1M / 2M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 77.14
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 221
- Website
- https://www.uniqure.com
Valuation
Metric | QURE |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 5.66 |
Price/Sales | 77.14 |
Price/Cash Flow | — |
Price/Earnings
QURE
Financial Strength
Metric | QURE |
|---|---|
Quick Ratio | 11.19 |
Current Ratio | 11.52 |
Interest Coverage | −3.48 |
Quick Ratio
QURE
Profitability
Metric | QURE |
|---|---|
Return on Assets (Normalized) | −23.90% |
Return on Equity (Normalized) | −88.31% |
Return on Invested Capital (Normalized) | −58.78% |
Return on Assets
QURE
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|Shg!Y?k | LOCK|v#C#q | $137B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|#?$NrM | LOCK|J<&! | $99B | |||
| Moderna Inc MRNA | LOCK|d<$@y$? | LOCK|%# | $90B | |||
| argenx SE ADR ARGX | LOCK|!cVbv! | LOCK|hQ | $61B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|g<#%J> | LOCK|X$ | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|^rwJmsV | LOCK|MZj? | $31B | |||
| Incyte Corp INCY | LOCK|M>qd?g | LOCK|Sk | $25B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|s!N<?& | LOCK|>StT | $22B | |||
| BioNTech SE ADR BNTX | LOCK|!@n!jYC | LOCK|t$ | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|x^MPb%L | LOCK|&VJ | $16B |
United States